Antiviral treatment of influenza in children

Pediatric Infectious Disease Journal

Volumn 31, Issue 2, 2012, Pages

  Garg, Shikha ^a,b   Fry, Alicia M ^b   Patton, Monica ^b   Fiore, Anthony E ^b   Finelli, Lyn ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Antiviral treatment; Children; Influenza; Oseltamivir

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIMANTADINE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ABDOMINAL DISCOMFORT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BRONCHOSPASM; DIAGNOSTIC TEST; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA A; INFLUENZA B; INTENSIVE CARE UNIT; LUNG DISEASE; MORBIDITY; NAUSEA AND VOMITING; PANDEMIC INFLUENZA; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VOMITING;

ANTIVIRAL AGENTS; CHILD; HUMANS; INFLUENZA, HUMAN; UNITED STATES;

EID: 84858126768     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824671ab     Document Type: Review

References (126)

1. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
2. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med. 1978;298:587-592. (Pubitemid 8291640)
3. Glezen WP, Decker M, Joseph SW, et al. Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983. J Infect Dis. 1987;155:1119-1126. (Pubitemid 17080484)
4. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002;185:147-152. (Pubitemid 34056437)
5. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239. (Pubitemid 30058954)
6. Dawood FS, Fiore A, Kamimoto L, et al. Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. J Pediatr. 2010;157:808-814.
7. Neuzil KM, Wright PF, Mitchel EF Jr, et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856-864.
8. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113:585-593. (Pubitemid 38280802)
9. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007;150:306 -310.
10. Ekstrand JJ, Herbener A, Rawlings J, et al. Heightened neurologic complications in children with pandemic H1N1 influenza. Ann Neurol. 2010;68:762-766.
11. Dawood FS, Fiore A, Kamimoto L, et al. Influenza-associated pneumonia in children hospitalized with laboratory-confirmed influenza, 2003-2008. Pediatr Infect Dis J. 2010;29:585-590.
12. Bratincsak A, El-Said HG, Bradley JS, et al. Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children. J Am Coll Cardiol. 2010;55:928 -929.
13. Ampofo K, Herbener A, Blaschke AJ, et al. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J. 2010;29:905-909.
14. Dawood FS, Kamimoto L, Bramley A, et al. Complications of seasonal and pandemic influenza in children hospitalized with influenza, 2003-2009. In: Pediatric Academic Societies Annual Meeting; 2010; Vancouver, British Columbia, Canada. Abstract 4325.3.
15. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340. (Pubitemid 39223224)
16. Cox CM, Kamimoto L, D'Mello T, et al. Pediatric influenza hospitalizations during the 2009 H1N1 pandemic, United States, April 2009-April 2010. In: Pediatric Academic Societies Annual Meeting; 2011; Denver, CO.
17. Louie JK, Gavali S, Acosta M, et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med. 2010;164:1023-1031.
18. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006;118:2409-2417. (Pubitemid 46397581)
19. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-2615.
20. Centers for Disease Control and Prevention. FluView: week ending May 22, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at: http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/weekly20. htm. Accessed February 15, 2010.
21. Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007;119:740 -748.
22. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-1944.
23. Kumar S, Havens PL, Chusid MJ, et al. Clinical and epidemiologic characteristics of children hospitalized with 2009 pandemic H1N1 influenza A infection. Pediatr Infect Dis J. 2010;29:591-594.
24. Bettinger JA, Sauve LJ, Scheifele DW, et al. Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases. Vaccine. 2010;28:3180-3184.
25. Libster R, Bugna J, Coviello S, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med. 2010;362:45-55.
26. Bagdure D, Curtis DJ, Dobyns E, et al. Hospitalized children with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for admission to the ICU. PloS One. 2010;5:e15173.
27. Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. Pediatr Infect Dis J. 2006;25:395-400.
28. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298:2155-2163. (Pubitemid 350106654)
29. Cox CM, Blanton L, Dhara R, et al. 2009 Pandemic influenza A (H1N1) deaths among children-United States, 2009-2010. Clin Infect Dis. 2011;52:s69-s74.
30. Mustaquim D, Bishop A, Epperson S, et al. Update: influenza activity - United States, 2009-10 season [reprinted from Morb Mortal Wkly Rep. 2010;59:901-908]. JAMA. 2010;304:957-960.
31. Miller MA, Viboud C, Balinska M, et al. The signature features of influenza pandemics implications for policy. N Engl J Med. 2009;360:2595-2598.
32. WHO Report. Available at: www.who.int/influenza/surveillance-monitoring/ 2010-2011-GIP-surveillance-seasonal-review/en/index.html. Accessed November 23, 2011.
33. Sachedina N, Donaldson LJ. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet. 2010;376:1846 -1852.
34. Centers for Disease Control and Prevention. Influenza-associated pediatric deaths - United States, September 2010-August 2011. Morb Mortal Wkly Rep. 2011;60:1233-1238.
35. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1-60.
36. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1-62.
37. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine. 2009;27:1101-1110.
38. Neuzil KM, Dupont WD, Wright PF, et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20:733-740. (Pubitemid 32758013)
39. Eisenberg KW, Szilagyi PG, Fairbrother G, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics. 2008;122:911-919.
40. Centers for Disease Control and Prevention. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine - Marshfield, Wisconsin, 2007-08 influenza season. Morb Mortal Wkly Rep. 2008;57:393-398.
41. Bate J, Yung CF, Hoschler K, et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis. 2010;51:e95-e104.
42. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;48:289-296.
43. Centers for Disease Control and Prevention. Final estimates for 2009 -10 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage-United States, August 2009 through May, 2010. Atlanta, GA: US Department of Health and Huma Services, CDC; 2010. Available at: http://www.cdc.gov/flu/professionals/vaccination/coverage-0910estimates.htm. Accessed February 15, 2011.
44. Centers for Disease Control and Prevention. Interim results: state-specific influenza vaccination coverage - United States, August 2010-February 2011. Morb Mortal Wkly Rep. 2011;60:737-743.
45. Centers for Disease Control and Prevention. Seasonal influenza vaccination coverage among children aged 6 months-18 years - eight immunization information system sentinel sites, United States, 2009-10 influenza season. Morb Mortal Wkly Rep. 2010;59:1266-1269.
46. Fiore AE, Fry AM, Shay DK, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2011;60:1-24.
47. Policy statement-recommendations for prevention and control of influenza in children, 2010-2011. Pediatrics. 2010;126:816-826.
48. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249 -257.
49. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891-894.
50. Centers for Disease Control and Prevention. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. Morb Mortal Wkly Rep. 2006;55:44-46.
51. Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J. 2010;29:195-198.
52. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Geneva, Switzerland; 2010.
53. Acosta EP, Kimberlin DW. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin Pharmacol Ther. 2010;88:704-707.
54. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis. 2010;202:563-566.
55. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133. (Pubitemid 32151932)
56. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51:887- 894.
57. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-417. (Pubitemid 30307990)
58. Winther B, Block SL, Reisinger K, et al. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. Int J Pediatr Otorhinolaryngol. 2010;74:684-688.
59. Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ. 2009;339:b3172.
60. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998;352:1877-1881.
61. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-880. (Pubitemid 27408569)
62. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-1024. (Pubitemid 30112215)
63. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-1850. (Pubitemid 30311875)
64. Barr CE, Schulman K, Iacuzio D, et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007;23:523-531. (Pubitemid 46456900)
65. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed. 2007;9:23.
66. Gums JG, Pelletier EM, Blumentals WA. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children. Expert Opin Pharmacother. 2008;9:151-161. (Pubitemid 351233727)
67. Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24:225-232. (Pubitemid 40365856)
68. Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65:1330-1346.
69. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-1672. (Pubitemid 36898954)
70. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011;53:277-279.
71. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124:170 -178.
72. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10:521-526.
73. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005;24:931-932. (Pubitemid 41475935)
74. Farias JA, Fernandez A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36:1015-1022.
75. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44:964-967. (Pubitemid 46452062)
76. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther. 2007;12:501-508. (Pubitemid 47041148)
77. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568 -1575.
78. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ. 2010;182:257-264.
79. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896-1902.
80. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302:1880-1887.
81. Yang P, Deng Y, Pang XH, et al. Severe, critical and fatal cases of 2009 H1N1 influenza in China. J Infect. 2010;61:277-283.
82. Skarbinski J, Jain S, Bramley A, et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States - September-October 2009. Clin Infect Dis. 2011;52:S50 -S59.
83. Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362:27-35.
84. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol. 2010;115:717-726.
85. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303:1517-1525.
86. Lee N, Cockram CS, Chan PK, et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis. 2008;46:1323-1324. (Pubitemid 351589924)
87. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240 -1246.
88. Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50:707-714.
89. Wilkes JJ, Zaoutis TE, Keren R, et al. Treatment with oseltamivir in children hospitalized with community-acquired, laboratory-confirmed influenza: review of five seasons and evaluation of an electronic reminder. J Hosp Med. 2009;4:171-178.
90. Herigon J, Newland J, Hersh AL. The impact of 2009 H1N1 influenza on antiviral prescribing for hospitalized children. In: Infectious Diseases Society of America Annual Meeting; 2010; Vancouver, British Columbia, Canada. Abstract 589.
91. Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet. 2011;377:1264-1275.
92. Centers for Disease Control and Prevention. Role of laboratory diagnosis of influenza. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at: http://www.cdc.gov/flu/professionals/diagnosis/labrole.htm. Accessed on February 16, 2011.
93. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354:1277-1282. (Pubitemid 29469365)
94. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis. 2009;48:e89-e92.
95. Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;361:2493.
96. Hawkes M, Richardson SE, Ipp M, et al. Sensitivity of rapid influenza diagnostic testing for swine-origin 2009 a (H1N1) influenza virus in children. Pediatrics. 2010;125:e639-e644.
97. Kok J, Blyth CC, Foo H, et al. Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol. 2010;48:290-291.
98. Abanses JC, Dowd MD, Simon SD, et al. Impact of rapid influenza testing at triage on management of febrile infants and young children. Pediatr Emerg Care. 2006;22:145-149.
99. Benito-Fernandez J, Vazquez-Ronco MA, Morteruel-Aizkuren E, et al. Impact of rapid viral testing for influenza A and B viruses on management of febrile infants without signs of focal infection. Pediatr Infect Dis J. 2006;25:1153-1157. (Pubitemid 44900679)
100. Bonner AB, Monroe KW, Talley LI, et al. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics. 2003;112:363-367. (Pubitemid 36951400)
101. Byington CL, Castillo H, Gerber K, et al. The effect of rapid respiratory viral diagnostic testing on antibiotic use in a children's hospital. Arch Pediatr Adolesc Med. 2002;156:1230 -1234.
102. Esposito S, Marchisio P, Morelli P, et al. Effect of a rapid influenza diagnosis. Arch Dis Child. 2003;88:525-526. (Pubitemid 36648947)
103. Sharma V, Dowd MD, Slaughter AJ, et al. Effect of rapid diagnosis of influenza virus type a on the emergency department management of febrile infants and toddlers. Arch Pediatr Adolesc Med. 2002;156:41-43. (Pubitemid 34049109)
104. Reed C, Kallen AJ, Patton M, et al. Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children. Pediatr Infect Dis J. 2009;28:572-576.
105. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122:805- 811.
106. Centers for Disease Control and Prevention. FluView: a weekly influenza surveillance report prepared by the influenza division. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at: http://www.cdc.gov/flu/weekly. Accessed August 25, 2011.
107. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48:389-396.
108. Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis. 2011;52:432-437.
109. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-765. (Pubitemid 39165094)
110. Shin SY, Kang C, Gwack J, et al. Drug-resistant pandemic (H1N1) 2009, South Korea. Emerg Infect Dis. 2011;17:702-704.
111. Centers for Disease Control and Prevention. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients -Seattle, Washington, 2009. Morb Mortal Wkly Rep. 2009;58:893-896.
112. Couturier BA, Bender JM, Schwarz MA, et al. Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients. Influenza Other Respi Viruses. 2010;4:199 -204.
113. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis. 2010;50:1493-1496.
114. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis. 2011;203:18-24.
115. Le QM, Wertheim HF, Tran ND, et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med. 2010;362:86-87.
116. Chen LF, Dailey NJ, Rao AK, et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis. 2011;203:838-846.
117. Relenza (zanamivir for inhalation) [package insert]. Research Triangle Park, NC: Glaxo Wellcome, Inc.; 2009.
118. Tamiflu (oseltamivir phosphate) capsules and oral suspension [package insert]. Nutley, NJ: Roche Laboratories, Inc.; 2009.
119. Kitching A, Roche A, Balasegaram S, et al. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009-an internet-based cross-sectional survey. Euro Surveill. 2009;14:19287.
120. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J. 2010;29:495-498.
121. Okumura A, Kubota T, Kato T, et al. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J. 2006;25:572. (Pubitemid 43863379)
122. Nakamura K, Schwartz BS, Lindegardh N, et al. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis. 2010;50:e47- e49.
123. German-Diaz M, Pavo-Garcia R, Diaz-Diaz J, et al. Adolescent with neuropsychiatric symptoms associated with novel influenza A (H1N1) virus infection. Pediatr Infect Dis J. 2010;29:570 -571.
124. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512-517.
125. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31:1097-1114.
126. Casscells SW, Granger E, Kress AM, et al. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21:79-89.